The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Merck, a leading science and technology company, today provided an update on the progress of the company’s innovative oncology development pipeline focused on DNA damage biology. With clinical programs designed to further advance standards of care in core tumors and assess the potential of novel mechanisms of action, including an industry-leading portfolio of DNA Damage Response inhibitors (DDRi), the company continues to build its focused leadership in the oncology space.
“Within our clinical-stage pipeline and our discovery programs, we have the opportunity to unlock and address DNA biology and apply a diversity of mechanisms to the treatment of multiple cancers
BACK
ABOUT US
COMPANYStrategy & ValuesManagementMerck HistoryBreakthroughs begin with CuriosityMerck in GermanyMerck LocationsContact UsSUSTAINABILITYProducts & InnovationBusiness EthicsHealth for AllEnvironmentEmployeesCommunity EngagementReports & GuidelinesSustainability ReportPARTNERINGCollaboration in HealthcareCollaboration in Life ScienceCollaboration in ElectronicsAcceleratorM VenturesProcurement
BACK
EXPERTISE
HEALTHCAREOncologyNeurology & ImmunologyFertilityEndocrinologyGeneral MedicineVibrant Thoughts BlogLIFE SCIENCEPharma BiotechDiagnosticsAcademic and Government ResearchIndustrialELECTRONICSSemiconductor SolutionsDisplay SolutionsSurface SolutionsArchitectureAutomotive
BACK
SCIENCE & TECH
RESEARCHOur R&D ApproachHealthcare PipelineClinical TrialsGlobal R&D HubsArtificial Intelligence - AI ResearchINNOVATION CENTERInnovation FieldsProject HighlightsGet involved!NewsEventsOPEN INNOVATIONFuture Insight Prize2022 Research Grants2022 Research ChallengesInnovation CupGrants and AwardsAll Open Innovation OffersSCIENCE SPACEEnvisioning TomorrowExperience our ResearchScience Library - Patents & Publications
Ralph. Interesting. So are you saying the 2 are linked? If so could we have possibly an rns this week Bout it?
Thanks Ralph
Is the Merck update linked to the previous PYC RNS before Christmas?
I just posted this on Pyc Telegram bb.
13 Dec contract with Merck
“These projects are expected to be completed over the course of the next six months and will span a range of drug targets and treatment types in both pre-clinical and clinical settings with a particular focus on DNA damage and repair (“DDR”) agents.”
3rd June Merck announces,
New data from DNA Damage Response (DDR) inhibitor portfolio inform development path for this promising biology
Clinical trials in locally advanced head and neck cancer and advanced bladder cancer seek to advance standards of care
https://www.merckgroup.com/en/news/development-projects-in-oncology-03-06-2022.html
https://www.bbc.co.uk/iplayer/episode/m0017wzq/horizon-2022-making-sense-of-cancer-with-hannah-fry
interesting as the conclusion is that "one size fits all" mantra of Cancer treatment, should be superseded by a different approach, a approach that PYC have advocated for sometime.
Also, S4, that was your funniest (in a good way ) post yet.
shame you guys can't "report" the share price.
Hi Siennaj, I've got one from you on Tuesday at 00:13 an d one from Laura at 07:43 also on Tuesday. The next one I've got yours at 13:53 on Thursday. More than one poster removed I think. I didn't read any thing contentious in any of the posts. All a bit strange!
Correct, i believe Tuesday posts have all gone.
I posted a few things on Tuesday and now gone.
I think LSE had a glitch on Tuesday night and maybe they got wiped. Not sure if other tickers have had the same issue?
The last post showing my end was 2 days ago by Laura.i am certain there were couple after that including one from me?? Anyone shed any light?
Morning Siemna
I think it was Kidlington who said VAL was an added bonus ,and that it's it's other deals which are more straightforward, this was from the investor Q and A from March which I found a few weeks ago
The pipeline is genuinely the strongest it’s ever been. For the first time, we’ve really been able to quantify that by disclosing that we have contracted revenue of over £460,000 for this half that we’re in now. We’ve never been able to say that before. We’ve never had that degree of visibility for the next five months. And obviously that’s just the revenues that we have signed up at this point in time.
Above these contracted revenues in the pyramid of Business Development we have a number of contracts that are in discussion, one of which is with another big pharma Company. If we can clinch that one, that is another very exciting opportunity and could be a big step forward for the Company. But it’s not the only opportunity
Laura. I'm not convinced the val thing will come ro anything? I have some shares in val but this deal has gone on and on and on and still not signed up but Suzy who is the main woman in the company seems to have the gift of the gab and has too much time on her hands which is evident from her constantly responding to shareholders e mails. She should be selling and get the pr machine to reply. Just my thoughts
Morning Kidlington and everyone
I may be wrong by looking back at the last 6mths of news we could/sould be due
1 more Merck deals as stated in the update late 2021
2 a bonus VAL 201 windfall (the last VAL news said before June 2022 and first revenues soon after
3 PYC mentioned a large pharma client (any guesses from the regulars here ?)in their March results and given we are Jne nearly this could be close
4 news on the purchaser buying DoseMeRX from Tabula Rasa
Please correct or amend if I have gotten things wrong above
Good to hear someone is buying.
Recently main buys have been in to the 20k area. However, on Friday, a tiny 4k buy pushed the SP up 1.4%, only for it to get ambushed again by the pesky 50k seller, there have also been sells of 100k and 100k+ recently. We ended red on Friday, the lowest point for a few years now, support was 4.1.
I await for news.
Entirely up yourself Sienna
We have been buying regualry over last 2mths as £4mln market value seems so undervalued when compared to the progress made
In addition, the Company has a strong pipeline of projects in advanced discussion, including one with a potential new large pharmaceutical client.
Thanks.
May b time to top up then?
Absolutely....it was my husband who mentioned PYC back in early 2022 , the last 5 or so PYC show a company on the verge of real recognition amd global recognition
Other posters on here have been very helpful
Thanks Laura.
I've noticed you seem to have good medical knowledge and you appear to have researched this company.
Do you think pyc could b on the threshold of something major now?
Sorry tobhear your loss
My husband is in healthcare and the industry is hell bent on tacking cancer once and for all.
He say tech that can cut time and cost of cancer drugs are getting large public and private funding
I'm new to PYC but can see the last 2yrs have been impressive foundations
I'm currently in PYC and SCLP
Laura. You are no doubt right about the figures you quote. I don't bother checking anymore. My dad had a lot of faith in pyc and he died in March 2011. That's 11 years ago so I've only stayed here with a modest amount of shares . But hey they may have turned the corner. Hope they have . Have a good weekend
In addition
The combined salaries are one of lowest on AIM
Losses.one of lowest
Cash burn on ONGOING activities (not recruitment etc) a mere £40k per annum
Maybe check these all in the results Sienna
Very etrwjge comment when VAL and SAR are not really comparable apart from being bio techs and VAL happens to be using PYC for modelling of one of its many drugs
PYC has just announced record H1 revenues and due for record H2 revenues
Aim is just crammed with crap companies like this one who have a long history of executives milking shareholders and delivering zero. I'm fed up with the parasites who feed on private shareholders. This company does my box in. I'm 60 now and will probably still b holding at 70 when share price will possibly reached 5p in expectation of this company holding the cure for every disease known to the human race. Same as Sar and Val. Seriously cheesed off with constant empty promises!!!!
AIM is fooked at the moment....
I have said my piece on this VAL201 deal before, however, although the post may have been "tongue in cheek" i would take a jcb bucket sized dose of salt to a comment that a particular company has informed a investor that funding has been completed.